- Home
- CTRE vs TLX Comparison
CTRE vs TLX Comparison
Compare CTRE & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRE
- TLX
- Stock Information
- Founded
- CTRE 2013
- TLX 2015
- Country
- CTRE United States
- TLX Australia
- Employees
- CTRE N/A
- TLX N/A
- Industry
- CTRE Real Estate Investment Trusts
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- CTRE Real Estate
- TLX Health Care
- Exchange
- CTRE Nasdaq
- TLX Nasdaq
- Market Cap
- CTRE 5.7B
- TLX 5.7B
- IPO Year
- CTRE N/A
- TLX N/A
- Fundamental
- Price
- CTRE $28.74
- TLX $16.99
- Analyst Decision
- CTRE Buy
- TLX Strong Buy
- Analyst Count
- CTRE 7
- TLX 1
- Target Price
- CTRE $30.86
- TLX $22.00
- AVG Volume (30 Days)
- CTRE 1.5M
- TLX 20.6K
- Earning Date
- CTRE 05-01-2025
- TLX 01-01-0001
- Dividend Yield
- CTRE 4.66%
- TLX N/A
- EPS Growth
- CTRE 73.08
- TLX 798.14
- EPS
- CTRE 0.95
- TLX 0.09
- Revenue
- CTRE $329,837,000.00
- TLX $484,687,790.00
- Revenue This Year
- CTRE $16.31
- TLX N/A
- Revenue Next Year
- CTRE $21.22
- TLX N/A
- P/E Ratio
- CTRE $30.25
- TLX $183.81
- Revenue Growth
- CTRE 43.26
- TLX 55.85
- 52 Week Low
- CTRE $24.35
- TLX $13.61
- 52 Week High
- CTRE $33.15
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- CTRE 50.51
- TLX N/A
- Support Level
- CTRE $28.26
- TLX N/A
- Resistance Level
- CTRE $29.36
- TLX N/A
- Average True Range (ATR)
- CTRE 0.62
- TLX 0.00
- MACD
- CTRE -0.06
- TLX 0.00
- Stochastic Oscillator
- CTRE 49.88
- TLX 0.00
About CTRE CareTrust REIT Inc.
CareTrust REIT Inc is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, financing, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.